1
Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma
Condition(s):Smoldering Plasma Cell MyelomaLast Updated:September 8, 2023Recruiting
Smoldering Plasma Cell Myeloma: 113 Clinical Trials, Page 1 of 12
Hide Studies Not Open or Pending
2
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
Condition(s):Smoldering Plasma Cell MyelomaLast Updated:July 3, 2023Active, not recruiting
3
Denosumab for Smoldering Multiple Myeloma
Condition(s):Smoldering Multiple MyelomaLast Updated:February 15, 2023Active, not recruiting
4
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Condition(s):Smoldering Plasma Cell MyelomaLast Updated:May 17, 2023Recruiting
5
Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
Condition(s):Smoldering Plasma Cell MyelomaLast Updated:November 14, 2019Withdrawn
6
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Condition(s):Smoldering Plasma Cell MyelomaLast Updated:June 23, 2023Recruiting
7
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Condition(s):Smoldering Plasma Cell MyelomaLast Updated:June 12, 2023Recruiting
8
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Condition(s):Smoldering Multiple MyelomaLast Updated:September 7, 2023Recruiting
9
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Condition(s):Smoldering Multiple MyelomaLast Updated:June 13, 2023Completed
10
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Condition(s):High Risk Smoldering Multiple MyelomaLast Updated:December 16, 2020Terminated